Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
BBM-D101 in Muscular Dystrophy, Duchenne: NCT06641895 Clinical Landscape Report 2026
16 September 2026
NCT06641895 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HG-302 in Muscular Dystrophy, Duchenne: NCT06594094 Clinical Landscape Report 2026
16 September 2026
NCT06594094 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Mesothelioma: NCT06638931 Clinical Landscape Report 2026
16 September 2026
NCT06638931 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NAX-035 in Malignant Pleural Mesothelioma: NCT06652529 Clinical Landscape Report 2026
16 September 2026
NCT06652529 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Empagliflozin in DMD-Associated Dilated Cardiomyopathy: NCT06643442 Clinical Landscape Report 2026
16 September 2026
NCT06643442 clinical landscape for DMD-Associated Dilated Cardiomyopathy: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
β-globin restored autologous hematopoietic stem cells (Hemogen Gene) in Beta-Thalassemia: NCT06655662 Clinical Landscape Report 2026
16 September 2026
NCT06655662 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Alrizomadlin in Mesothelioma, Malignant: NCT06654050 Clinical Landscape Report 2026
16 September 2026
NCT06654050 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tacrolimus in Muscular Dystrophy, Duchenne: NCT06692426 Clinical Landscape Report 2026
16 September 2026
NCT06692426 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tezepelumab in Severe asthma: NCT06705764 Clinical Landscape Report 2026
16 September 2026
NCT06705764 clinical landscape for Severe asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
β-globin restored autologous hematopoietic stem cells (Hemogen Gene) in Beta-Thalassemia: TCTR20241029003 Clinical Landscape Report 2026
16 September 2026
TCTR20241029003 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vamorolone in Muscular Dystrophy, Duchenne: NCT06713135 Clinical Landscape Report 2026
16 September 2026
NCT06713135 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[203Pb]PSV359 in Sarcoma: NCT06710756 Clinical Landscape Report 2026
16 September 2026
NCT06710756 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.